Last reviewed · How we verify
Sore throat symptom — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Delsym | dextromethorphan | Generic (originally Roche) | Antitussive (non-opioid) | Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6 | 1958-01-01 | |
| Codeine | codeine phosphate | Generic (multiple manufacturers) | Opioid analgesic, Antitussive | Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor | 1950-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Sore throat symptom
- Generic (multiple manufacturers) · 1 drug in Sore throat symptom
- Generic (originally Roche) · 1 drug in Sore throat symptom
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Sore throat symptom:
- Sore throat symptom treatment updates — RSS
- Sore throat symptom treatment updates — Atom
- Sore throat symptom treatment updates — JSON
Cite this brief
Drug Landscape (2026). Sore throat symptom — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sore-throat-symptom. Accessed 2026-06-10.
Related
- Sore throat symptom full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing